Jones Financial Companies Lllp Buys 58 Shares of Insulet Co. (NASDAQ:PODD)

Jones Financial Companies Lllp boosted its stake in Insulet Co. (NASDAQ:PODD) by 3.9% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 1,527 shares of the medical instruments supplier’s stock after acquiring an additional 58 shares during the period. Jones Financial Companies Lllp’s holdings in Insulet were worth $399,000 at the end of the most recent reporting period.

Several other large investors have also added to or reduced their stakes in the stock. Baillie Gifford & Co. boosted its holdings in Insulet by 3.5% in the fourth quarter. Baillie Gifford & Co. now owns 2,355,683 shares of the medical instruments supplier’s stock valued at $614,998,000 after acquiring an additional 79,982 shares in the last quarter. Geode Capital Management LLC boosted its holdings in shares of Insulet by 1.3% during the 3rd quarter. Geode Capital Management LLC now owns 1,738,601 shares of the medical instruments supplier’s stock valued at $403,339,000 after buying an additional 22,850 shares in the last quarter. Westfield Capital Management Co. LP boosted its holdings in shares of Insulet by 27.6% during the 3rd quarter. Westfield Capital Management Co. LP now owns 754,872 shares of the medical instruments supplier’s stock valued at $175,697,000 after buying an additional 163,388 shares in the last quarter. Charles Schwab Investment Management Inc. boosted its holdings in shares of Insulet by 43.8% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 636,265 shares of the medical instruments supplier’s stock valued at $148,091,000 after buying an additional 193,839 shares in the last quarter. Finally, Fisher Asset Management LLC boosted its holdings in shares of Insulet by 7.6% during the 4th quarter. Fisher Asset Management LLC now owns 377,694 shares of the medical instruments supplier’s stock valued at $98,605,000 after buying an additional 26,594 shares in the last quarter.

Insiders Place Their Bets

In other news, EVP Eric Benjamin sold 12,394 shares of the company’s stock in a transaction dated Tuesday, January 21st. The shares were sold at an average price of $280.00, for a total transaction of $3,470,320.00. Following the completion of the sale, the executive vice president now owns 11,383 shares of the company’s stock, valued at $3,187,240. This represents a 52.13 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 0.47% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

A number of brokerages have recently commented on PODD. JPMorgan Chase & Co. boosted their target price on shares of Insulet from $280.00 to $330.00 and gave the company an “overweight” rating in a report on Thursday, December 12th. Raymond James restated an “outperform” rating and set a $328.00 target price (up previously from $294.00) on shares of Insulet in a report on Friday, February 21st. Royal Bank of Canada began coverage on shares of Insulet in a report on Thursday, March 6th. They set an “outperform” rating and a $340.00 target price on the stock. Canaccord Genuity Group boosted their target price on shares of Insulet from $304.00 to $324.00 and gave the company a “buy” rating in a report on Friday, February 21st. Finally, Citigroup boosted their target price on shares of Insulet from $310.00 to $355.00 and gave the company a “buy” rating in a report on Friday, February 21st. Four research analysts have rated the stock with a hold rating and fourteen have given a buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $292.06.

Insulet Price Performance

Shares of NASDAQ:PODD opened at $245.35 on Wednesday. Insulet Co. has a fifty-two week low of $160.19 and a fifty-two week high of $289.46. The business has a 50-day simple moving average of $273.25 and a two-hundred day simple moving average of $254.12. The company has a debt-to-equity ratio of 1.21, a quick ratio of 2.80 and a current ratio of 3.68. The firm has a market cap of $17.23 billion, a price-to-earnings ratio of 42.37, a price-to-earnings-growth ratio of 3.62 and a beta of 1.29.

Insulet (NASDAQ:PODD) last issued its earnings results on Thursday, February 20th. The medical instruments supplier reported $1.15 earnings per share for the quarter, topping analysts’ consensus estimates of $1.00 by $0.15. Insulet had a return on equity of 24.46% and a net margin of 20.19%. The business had revenue of $597.50 million during the quarter, compared to analyst estimates of $582.02 million. On average, analysts expect that Insulet Co. will post 3.92 earnings per share for the current year.

Insulet Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.